Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levcromakalim provocation in migraine with aura
NCT04905654Completed
- Sponsor
- Dansk Hovedpinecenter
- Start
- Sep 2021
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of levcromakalim (2 arms), sponsored by Dansk Hovedpinecenter. Primary endpoints: Headache incidence at 24 hours, Migraine incidence at 24 hours and 1 more. Started Sep 2021; status: completed.
02
Drugs
levcromakalim
Beyond the preview
Go deeper on NCT04905654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04905654.